Understand the source comparison
New Year Peptide Plan Reset Protocol January: Peptide Class Comparison
Before implementing any reset protocol, understand how washout requirements and reintroduction strategies differ across compound classes. GH Secretagogues (Ghrelin Mimetics) MK 677, GHRP-2, Hexarelin 14–21 60% of maintenance dose GHSR-1a upregulation measurabl
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before implementing any reset protocol, understand how washout requirements and reintroduction strategies differ across compound classes.
- GH Secretagogues (Ghrelin Mimetics)
- MK 677, GHRP-2, Hexarelin
- 14–21
- 60% of maintenance dose
- GHSR-1a upregulation measurable at 14 days, optimal at 21
- Fastest receptor recovery. Can run shorter resets if necessary
- GHRH Analogs
- CJC-1295, Modified GRF(1-29)
- 21–28
- 70% of maintenance dose
- GHRH receptor recovery slower. Requires 21+ days for baseline restoration
- Longer washout critical. Skipping full reset reduces next cycle efficacy by 30%+
- Melanocortin Agonists
- Melanotan-II, PT-141
- 18–24
- 50% of maintenance dose
- MC4R desensitization reverses within 18–21 days; MC1R faster (14 days)
- Lower reintroduction dose prevents rapid tachyphylaxis during receptor stabilization phase
- Thymic Peptides
- Thymalin, Thymosin Alpha-1
- 28–42
- 80% of maintenance dose
- Immunomodulatory effects persist post-cessation. Receptor dynamics less characterized
- Longer washout recommended due to cascading immune signaling effects that outlast compound clearance
- Nootropic Peptides
- Cerebrolysin, Dihexa, P21
- Neuroplastic effects demonstrate long half-lives. Receptor normalization requires 3–4 weeks
- Cognitive effects may persist during washout; this isn't receptor presence but downstream pathway changes
- Metabolic Modulators
- Tesofensine, AOD-9604
- Monoamine transporter regulation normalizes rapidly. 14–18 days sufficient
- January's elevated baseline thermogenesis allows lower reintroduction doses without efficacy loss